160 related articles for article (PubMed ID: 37602543)
1. The Targeted Therapies for Osteosarcoma
Wang S; Ren Q; Li G; Zhao X; Zhao X; Zhang Z
Curr Mol Pharmacol; 2024; 17(1):e210823220109. PubMed ID: 37602543
[TBL] [Abstract][Full Text] [Related]
2. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.
Wang W; Zhao HF; Yao TF; Gong H
Invest New Drugs; 2019 Feb; 37(1):175-183. PubMed ID: 30353245
[TBL] [Abstract][Full Text] [Related]
3. Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.
Shaikh AB; Li F; Li M; He B; He X; Chen G; Guo B; Li D; Jiang F; Dang L; Zheng S; Liang C; Liu J; Lu C; Liu B; Lu J; Wang L; Lu A; Zhang G
Int J Mol Sci; 2016 Apr; 17(4):506. PubMed ID: 27058531
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Rocca M; Ferrari S; Donati D; Longhi A; Bertoni F; Bacchini P; Giacomini S; Forni C; Manfrini M; Galletti S
Ann Oncol; 2003 Jul; 14(7):1126-34. PubMed ID: 12853357
[TBL] [Abstract][Full Text] [Related]
5. Role of TKI for Metastatic Osteogenic Sarcoma.
Duffaud F
Curr Treat Options Oncol; 2020 Jun; 21(8):65. PubMed ID: 32601895
[TBL] [Abstract][Full Text] [Related]
6. Osteosarcoma Pathogenesis Leads the Way to New Target Treatments.
Fernandes I; Melo-Alvim C; Lopes-Brás R; Esperança-Martins M; Costa L
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467481
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
[TBL] [Abstract][Full Text] [Related]
8. mTOR: An attractive therapeutic target for osteosarcoma?
Ding L; Congwei L; Bei Q; Tao Y; Ruiguo W; Heze Y; Bo D; Zhihong L
Oncotarget; 2016 Aug; 7(31):50805-50813. PubMed ID: 27177330
[TBL] [Abstract][Full Text] [Related]
9. Calycosin, a Phytoestrogen Isoflavone, Induces Apoptosis of Estrogen Receptor-Positive MG-63 Osteosarcoma Cells via the Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Sun H; Yin M; Qian W; Yin H
Med Sci Monit; 2018 Sep; 24():6178-6186. PubMed ID: 30182951
[TBL] [Abstract][Full Text] [Related]
10. Molecular Signaling Pathways as Potential Therapeutic Targets in Osteosarcoma.
Dana PM; Sadoughi F; Asemi Z; Yousefi B
Curr Med Chem; 2022; 29(25):4436-4444. PubMed ID: 35139778
[TBL] [Abstract][Full Text] [Related]
11. Is CDK9 a promising target for both primary and metastatic osteosarcoma?
Qin JJ
EBioMedicine; 2019 Feb; 40():27-28. PubMed ID: 30651218
[No Abstract] [Full Text] [Related]
12. Anti-tumoral potential of MDA19 in human osteosarcoma via suppressing PI3K/Akt/mTOR signaling pathway.
Liu B; Xu L; Dai EN; Tian JX; Li JM
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30442873
[TBL] [Abstract][Full Text] [Related]
13. Response to Pazopanib in Patients With Relapsed Osteosarcoma.
Elete KR; Albritton KH; Akers LJ; Basha R; Ray A
J Pediatr Hematol Oncol; 2020 May; 42(4):e254-e257. PubMed ID: 30531600
[TBL] [Abstract][Full Text] [Related]
14. Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy.
Sakamoto A; Iwamoto Y
Rev Recent Clin Trials; 2008 Sep; 3(3):228-31. PubMed ID: 18782081
[TBL] [Abstract][Full Text] [Related]
15. Targeting the VEGF Pathway in Osteosarcoma.
Assi T; Watson S; Samra B; Rassy E; Le Cesne A; Italiano A; Mir O
Cells; 2021 May; 10(5):. PubMed ID: 34069999
[TBL] [Abstract][Full Text] [Related]
16. miR-155 Affects Osteosarcoma MG-63 Cell Autophagy Induced by Adriamycin Through Regulating PTEN-PI3K/AKT/mTOR Signaling Pathway.
Wang L; Tang B; Han H; Mao D; Chen J; Zeng Y; Xiong M
Cancer Biother Radiopharm; 2018 Feb; 33(1):32-38. PubMed ID: 29412697
[TBL] [Abstract][Full Text] [Related]
17. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
18. Rosmarinic acid exerts an anticancer effect on osteosarcoma cells by inhibiting DJ-1 via regulation of the PTEN-PI3K-Akt signaling pathway.
Ma Z; Yang J; Yang Y; Wang X; Chen G; Shi A; Lu Y; Jia S; Kang X; Lu L
Phytomedicine; 2020 Mar; 68():153186. PubMed ID: 32088353
[TBL] [Abstract][Full Text] [Related]
19. Innovative approaches for treatment of osteosarcoma.
Rothzerg E; Pfaff AL; Koks S
Exp Biol Med (Maywood); 2022 Feb; 247(4):310-316. PubMed ID: 35043695
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy for osteosarcoma: a review.
Li S; Zhang H; Liu J; Shang G
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6785-6797. PubMed ID: 36807762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
